6th Annual TIL Therapies Summit

Following the watershed approval of Iovances' Lifileucel, all eyes are now on TIL therapies as the up-and-coming major therapeutic avenue for solid tumor treatment.

The 6th Annual TIL Therapies Summit returns to Boston as the only meeting putting the entire spotlight on TIL drug development, giving you an unmissable opportunity to capitalize on the wave of excitement into this field, as the blockbuster potential of harnessing TILs is now realized with the regulatory seal of approval.

Join 30+ key industry speakers including Iovance Biotherapeutics, Obsidian Therapeutics, KSQ Therapeutics and the MD Anderson Cancer Center, as they unveil the latest to share clinical updates, next-generation candidates, manufacturing innovations, and assay characterizations to turbocharge development of the next wave of TIL therapies.

With a brand-new 2 tracked agenda, tailor your learning experience across pre-clinical and translation versus clinical strategy and manufacturing to leverage your entire team's expertise among laser focused stakeholders. This year will be the biggest edition yet, as the niche community rapidly expands to seize novel opportunities.

URLs:
Website: https://go.evvnt.com/2439241-0?pid=10018
Tickets: https://go.evvnt.com/2439241-2?pid=10018
Brochure: https://go.evvnt.com/2439241-3?pid=10018

Prices:
Conference + Workshop Day - Drug Developer Pricing: USD 4197.00,
Conference Only - Drug Developer Pricing: USD 2999.00,
Conference + Workshop Day - Solution Provider Pricing: USD 5197.00,
Conference Only - Solution Provider Pricing: USD 3699.00,
Conference + Workshop Day - Academic Pricing: USD 3697.00,
Conference Only - Academic Pricing: USD 2599.00

Speakers: Andrea Aran Garriga, Postdoctoral Researcher, Hospital Clinic Barcelona, Andrew Weinberg, President and Chief Scientific Officer, AgonOx, Branden Moriarity, Associate Professor, University of Minnesota, Cecilia Zhang, Chief Scientific Officer, Biosyngen, Derrell Porter, Chief Executive Officer, CTRL Therapeutics, Eduardo Davila, Chief Scientific Officer, Trampoline Pharma, Eric Chen, Founder and Chief Executive Officer, Achelois Biopharma, Friedrich Graf Finckenstein, Chief Medical Officer, Iovance, Gary Lee, Chief Scientific Officer, Lyell Immunopharma, George Coukos, Director - Branch, Ludwig Institute for Cancer Research, Ignacio Nunez, Chief Operating Officer, CellReady, James Yang, Senior Investigator, Steven Rosenberg Group, National Institute of Health, Janet Lynch, Lambert Advisor, Alliance for Regenerative Medicine, Jingwei Sun, Senior Director of Early Discovery, GRIT Biotechnology, Karrie Wong, Senior Director, Head of Cell Therapy, KSQ Therapeutics, Inc, Luca Gattinoni, Professor - Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Madan Jagasia, Chief Executive Officer, Obsidian Therapeutics, Marit Van Buuren, Senior Director - Transational Cell Immunology, BioNTech, Mark Dudley, Chief Scientific Officer, InstilBio UK, Markus Maeurer, Head of Immunotherapy, Champalimaud Foundation, Michael Lotze, Professor of Surgery, University of Pittsburgh, Nicholas Restifo, Co-Founder and Chief Scientist, Marble Therapeutics, Rodabe Amaria, Assistant Professor - Melanoma Medical Oncology, MD Anderson Cancer Center , Sean Hall, Director, Iovance Biotherapeutics Inc., Sergio Quezada, Chief Scientific Officer, Achilles Therapeutics, Ulrik Cordes, Founder, Chief Executive Officer, Cbio, Violetta Medik, Director of Analytical Development, KSQ, Yang Liu, Co-Founder, Hervor Therapeutics, Yarong Liu, Chief Executive Officer, GRIT Biotechnology, Yi Zhao, Chief Technology Officer and Chief Executive Officer, Sino-Cell Biomed